Quote:
Originally Posted by
altasnob
I totally get that we put out flu vaccines every year without clinical trials. And I get that Mofro, Summit, and Old Goat are all saying we should do the same for COVID vaccines. What I am wondering is why this Prof Sir Andrew Pollard guy, who apparently helped make the AstraZeneca vaccine, is telling me he disagrees with the stance of Mofro/Summit/Old Goat, et al?
When I dig in and try decipher why Sir Pollard thinks this way, I get:
"We haven't even managed to vaccinate everyone in Africa with one dose so we're certainly not going to get to a point where fourth doses for everyone is manageable."
He also states that at the current moment, he is not convinced the UK will ever need another booster shot, ever. He qualifies this statement by saying his opinion could change depending on what future variants emerge. And his statement is limited to the situation in the UK, not elsewhere.
You are confused again. I'm not talking a 4th dose, but a shift in antigenic coverage such that vaccines administered going forward as boosters, AND coverage for 3rd world countries can increase in efficacy towards the relevant circulating strains, isn't out of the question and is entirely plausible.
Quote:
Pfizer’s chief executive, Albert Bourla, made a bold promise in June. Standing next to US President Joe Biden at a press conference in St Ives, UK, just before the G7 summit meeting, Bourla said that should the need arise for a new COVID-19 vaccine, his company could get one ready within 100 days.
The need he was referring to is the possible emergence of an ‘escape variant’ — a dominant strain of SARS-CoV-2 that evades the fledgling immunity established through vaccines and previous infections. No such strain has yet been identified, but Pfizer and other leading COVID-19 vaccine makers are gearing up for that scenario.
What does it take to be nimble enough to design and test an updated vaccine against an unknown viral strain, in record time? Nature spoke to three COVID-19 vaccine makers — Pfizer, Moderna and AstraZeneca — to find out exactly how they are preparing.
Dress rehearsal
Over the past few months, all three companies have been running dress rehearsals by practising on known SARS-CoV-2 variants. This involves updating their vaccines to match variants such as Beta and Delta, testing them in clinical studies, tuning their internal workflows and coordinating with regulators. Their goal is to learn from these warm-up trials and smooth out kinks in their processes, so that they can move fast if, or when, a true escape variant emerges.
“At some point, inevitably, we’re going to have to make variant vaccines — if vaccines are the way population immunity will be maintained — but we’re not at the point where we can confidently predict the evolution of the virus,” says Paul Bieniasz, a virologist at the Rockefeller University in New York City. “Practising with existing variants seems like a reasonable approach.”